Comparative Study of Pharmacopoeias in Japan, Europe, and the United States: Toward the Further Convergence of International Pharmacopoeial Standards

Abstract

A pharmacopoeia's core mission is to protect public health by creating and making available public standards to help ensure the quality of drugs. In recent years, pharmacopoeias around the world have harmonized their standards in the present context of globalized drug supply chains and markets. For example, the Pharmacopoeial Discussion Group has worked to harmonize excipient monographs and general chapters. In addition, the International Meeting of World Pharmacopoeias has been held by the WHO to discuss information exchange and international collaboration, among other topics. To contribute further to the protection of public health in the globalized drug market, we conducted a comparative study of the pharmacopoeias in Japan, Europe, and the United States. We aimed to examine current differences among the Japanese Pharmacopoeia, the European Pharmacopoeia, and the United States Pharmacopeia-National Formulary and to identify areas that require further collaboration among the three pharmacopoeias. In this study, we analyzed monographs and general chapters listed in the three pharmacopoeias. We identified the features of the monographs and general chapters listed in each pharmacopoeia, as well as differences across the pharmacopoeias. Moreover, on the basis of our findings, we suggest standards that require further collaboration among the pharmacopoeias in certain preferred areas. The comparison data produced by this study are expected to be used to develop strategies for future revisions of pharmacopoeias around the world.

Identification of Koumine as a Translocator Protein 18 kDa Positive Allosteric Modulator for the Treatment of Inflammatory and Neuropathic Pain

“…A characteristic of allosteric modulators is their ability to bind receptors and modulate the binding and/or signaling efficacy of orthosteric ligands ( Wootten et al, 2013 ). SPR, a gold standard for real-time and label-free measurements of biomolecular interactions included in the pharmacopoeias of several countries, measuring affinity is its main application ( Kameyama et al, 2019 ). Since there is no isotope labeling of the koumine, the traditional radioligand binding experiment cannot be used to determine the affinity.…”

Pharmacopoeia roles and responses: A systemic resilience approach to COVID-19 pandemic

“…Similarly, the Indian Pharmacopoeia (IP) is the official book of drug standards as per the second schedule of the Drugs and Cosmetics Act, 1940 and Rules 1945 there under for obtaining marketing authorization in India ( Malik, 2014 ). The Japanese Pharmacopoeia (JP) is an official document that defines the specifications, criteria, and standard testing methods necessary to properly assure the quality of drugs in Japan, based on Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy, and Safety of Products including Pharmaceuticals and Medical Devices ( Kameyama et al, 2019 ). Also, the United States Pharmacopeia (USP) is used to control the quality of drugs distributed in the United States, as prescribed in Sections 201(g) and 501(b) of the Federal Food, Drug, and Cosmetic Act (USP, 2021).…”

Enrichment of Palmitoleic Acid by a Combination of Two-step Solvent Crystallization and Molecular Distillation

“…These solvents are permitted at parts-per-million ppm residual concentrations in pharmaceuticals according to the United States Pharmacopoeia USP . Methanol is a Class 2 solvent associated with an allowable concentration limit of 3000 ppm 21 . Acetone, a polar solvent, is commonly selected as crystallization solvent for the separation of triglycerides and free fatty acids 22 .…”